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Long non-coding RNAs (lncRNAs) have been proved to play important roles in the tumorigenesis and
development of several human malignancies. Our study aims to investigate the expression and function
of lncRNA-UCA1 in osteosarcoma. lncRNA-UCA1 expression was detected in osteosarcoma tissues and
cell lines by using qRT-PCR. Association between lncRNA-UCA1 levels and clinicopathological factors and
patient's prognosis was analyzed. The roles of lncRNA-UCA1 in regulating osteosarcoma cell proliferation,
apoptosis, migration, and invasion were evaluated in vitro. We found that lncRNA-UCA1 expression was
upregulated in osteosarcoma tissues and cell lines. High lncRNA-UCA1 expression was signiﬁcantly
correlated with large tumor size, high tumor grade, positive distant metastasis, and advanced clinical
stage. Multivariate regression analysis identiﬁed lncRNA-UCA1 overexpression as an independent un-
favorable prognostic factor. lncRNA-UCA1 knockdown inhibited osteosarcoma cell proliferation, pro-
moted cell apoptosis, and suppressed cell invasion and migration, whereas lncRNA-UCA1 overexpression
showed opposite effects. These ﬁndings suggested that lncRNA-UCA1 may contribute to osteosarcoma
initiation and progression, and would be not only a novel prognostic marker but also a potential ther-
apeutic target for this disease.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteosarcoma is one of the most common primary bone tumor
and occurs predominantly in children and young adults [1]. With the
development of multiple therapeutic strategies including wide tumor
excision, neoadjuvant or adjuvant chemotherapy, and radiotherapy,
the 5 year survival of the non-metastatic patients has increased to
65% [2]. However, osteosarcoma is very aggressive and approxi-
mately 40–50% of patients will eventually develop metastases,
especially pulmonary metastases [3]. The prognosis of these patients
is rather poor, and the long-term survival rate is only 10–30% [4]. The
complex molecular mechanisms underlying osteosarcoma tumor-
igenesis and progression remain largely unclear. Identiﬁcation of new
candidate molecules that take part in these processes is crucial for
developing new therapeutic approach for osteosarcoma and im-
proving clinical outcomes of patients with this disease.GmbH. This is an open access art
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an).Long noncoding RNAs (lncRNAs) are deﬁned as RNA tran-
scripts of more than 200 nucleotides in length with no or little
protein-coding capacity [5]. LncRNAs can regulate gene expres-
sion through diverse mechanisms including epigenetic silencing,
mRNA splicing, lncRNA-miRNA interaction, lncRNA-protein in-
teraction and lncRNA-mRNA interaction [6]. Recent studies
showed that lncRNAs are involved in a wide range of biological
processes, such as embryonic development, cell proliferation,
apoptosis, invasion, metastasis and angiogenesis [7–9]. Further-
more, lncRNAs can act as oncogenes or tumor suppressors, and
play important roles in carcinogenesis and cancer development
[10,11]. Abnormal lncRNA expression and its association with
various important clinicopathological parameters have been re-
ported in many types of cancers. In terms of osteosarcoma, in-
creased lncRNA FGFR3-AS1 expression correlated with large tu-
mor size, advanced Enneking stage, and poor survival [12].
Plasma lncRNA TUG1 contributed to osteosarcoma detection and
dynamic surveillance [13]. Silence of lncRNA TUSC7 promoted
osteosarcoma cell proliferation and increased colony formation in
vitro [14]. LncRNA ODRUL inhibition could inhibit osteosarcoma
cell proliferation and migration, and partly reversed doxorubicin
resistance [15]. Therefore, lncRNAs may be utilized for osteo-
sarcoma diagnosis and prognosis, and serve as potential ther-
apeutic targets.icle under the CC BY-NC-ND license
Table 1
Association of lncRNA-UCA1 expression with clinicopathological factors in
osteosarcoma.
Clinicopathological
features
Number of
cases
lncRNA-UCA1
expression
P
Low n (%) High n (%)
Age
o20 years 98 46(46.9%) 52(53.1%) 0.339
Z20 years 37 21(56.8%) 16(43.2%)
Gender
Male 95 49(51.6%) 46(48.4%) 0.573
Female 40 18(45.0%) 22(55.0%)
Tumor size
W. Li et al. / Journal of Bone Oncology 5 (2016) 80–85 81Urothelial carcinoma associated 1 (UCA1) is an lncRNA origin-
ally identiﬁed in human bladder carcinoma [16]. Overexpression of
UCA1 signiﬁcantly enhanced bladder cancer cell proliferation and
migration and confered drug resistance. Recently, UCA1 has been
reported to be upregulated and exert its oncogenic activity in
several cancers such as esophageal squamous cell carcinoma [17],
breast cancer [18], non-small cell lung cancer [19], gastric cancer
[20], colorectal cancer[21], hepatocellular carcinoma [22], renal
cell carcinoma [23], ovarian cancer [24], and prostate cancer [25].
However, the signiﬁcance of UCA1 in osteosarcoma is still unclear.
In the present study, we investigated the expression level of UCA1
in osteosarcoma samples and cell lines. We also investigated the
correlation between UCA1 expression and clinicopathological
characteristics and patient's survival. Moreover, we explored the
role of UCA1 in the regulation of biological behaviors of osteo-
sarcoma cells.48 cm 57 20(35.1%) 37(64.9%) 0.005
r8 cm 78 47(60.3%) 31(39.7%)
Anatomic location
Tibia/femur 93 48(51.6%) 45(48.4%) 0.512
Elsewhere 42 19(45.2%) 23(54.8%)
Tumor grade
Low 45 30(66.7%) 15(33.3%) 0.004
High 90 37(41.1%) 53(58.9%)
Histological type
Osteoblastic 52 28(53.8%) 24(46.2%) 0.774
Fibroblastic 26 11(42.3%) 15(57.7%)
Chondroblastic 20 9(45.0%) 11(55.0%)
Telangiectatic 21 12(57.1%) 9(42.9%)
Others 16 7(43.8%) 9(56.2%)
Enneking stage
I 35 27(77.1%) 8(22.9%) o0.001
II 66 32(48.5%) 34(51.5%)
III 34 8(23.5%) 26(76.5%)
Distant metastasis
Absent 101 58(57.4%) 43(42.6%) 0.002
Present 34 9(26.5%) 25(73.5%)2. Materials and methods
2.1. Patients and clinical specimens
Matched fresh osteosarcoma specimens and adjacent non-
tumorous tissues were acquired from 135 patients at Hanzhong
Municipal Central Hospital between January 2006 and December
2010. None of the patients received chemotherapy or radiotherapy
before sample collection. All specimens were frozen in liquid ni-
trogen immediately after collection and stored at 80 °C until use.
Table 1 showed the details of clinical and pathological character-
istics of the patients. The follow-up data were available and
complete for each patient. Overall survival was calculated from the
day of primary surgery to death or last follow-up. This project was
approved by the Clinical Research Ethics Committee of our hos-
pital and all patients provided written informed consent.
2.2. Cell culture
The normal osteoblast cell line hFOB1.19 and human osteo-
sarcoma cell lines (HOS, Saos-2, MG-63, U2OS) were purchased
from the Chinese Academy of Medical Sciences and cultured in
Dulbecco's modiﬁed Eagle's medium (DMEM, USA) supplemented
with 10% fetal bovine serum (FBS, USA), penicillin (100 U/ml), and
streptomycin (100 μg/ml). All cells were incubated at 37 °C in 5%
CO2.
2.3. RNA extraction and real-time PCR
Total RNA was extracted by Trizol reagent (Invitrogen, Carlsbad,
CA, USA). The ﬁrst-strand cDNA was synthesized from 1 μg of total
RNA using the Reverse Transcription System Kit (Takara, Dalian,
China). The real-time PCR was carried out using SYBR Premix Ex
Taq kit (Takara, Dalian, China) on an ABI 7500 Real-Time PCR
System (Applied Biosystems, CA, USA). Each assay was performed
in triplicate, and GAPDH was used as the endogenous control gene.
The primer sequences used were as follows: UCA1, 5′-TTCCTTAT-
TATCTCTTCTG-3′ (forward) and 5′-TCCATCATACGAATAGTA-3′ (re-
verse); GAPDH, 5′-CTCGCTTTGGCAGCA CA-3′ (forward) and 5′-
AACGCTTCACGAATTTGCGT-3′ (reverse). The relative amount of
UCA1 to GAPDH was calculated using the 2–ΔCt method, where
ΔCT ¼(CTUCA1 - CTGAPDH).
2.4. UCA1 knockdown and overexpression
The cDNA encoding UCA1 was PCR-ampliﬁed and subcloned
into the pCDNA3.1 vector (Invitrogen, Shanghai, China). The empty
pcDNA3.1 vector was used as the control. UCA1 small interferingRNA (si-UCA1) and negative control siRNA (si-NC) were synthe-
sized by GenePharma (Shanghai, China). Transfections were per-
formed using Lipofectamine 2000 according to the manufacturer's
instructions (Invitrogen, CA, USA).
2.5. Cell proliferation assay
Osteosarcoma cells were seeded into 96-well plates after
transfection. Cell density was adjusted to 5103/well, and the
ﬁnal volume was 150 μl/well. Cell proliferation was determined
every 24 h for 4 days. At the indicated time point, 20 μl of MTT
(Sigma, USA) was added into each well and the cells were cultured
for another 4 h at 37 °C. Then the supernatants were removed and
150 μl of DMSO was added. Optical density was detected at a
wavelength of 490 nm and each assay was repeated three times.
2.6. Detection of apoptosis by ﬂow cytometry
Cell apoptosis was measured by using an Annexin V-FITC
Apoptosis Detection kit (BD Biosciences, San Diego, CA) according
to the manufacturer's instructions. After transfection, osteosarco-
ma cells were harvested and washed twice with cold phosphate-
buffered saline. Then, the cells were treated with Annexin V/
Fig. 2. Kaplan-Meier survival curves of osteosarcoma patients based on lncRNA-
UCA1 expression levels. Patients in the high UCA1 expression group had sig-
niﬁcantly poorer prognosis than those in low UCA1 expression group (Po0.001,
log-rank test).
Table 2
Univariate and multivariate analysis of overall survival in 135 osteosarcoma
patients.
Variable Univariate analysis Multivariate analysis
HR p-value HR p-value
Age 1.528 0.225 – –
Gender 1.120 0.773 – –
W. Li et al. / Journal of Bone Oncology 5 (2016) 80–8582propidium iodide (PI) for 15 min in the dark at room temperature,
and analyzed by ﬂow cytometry assay.
2.7. Transwell invasion and migration assays
Cell invasion and migration assays were performed using the
24-well transwell chambers (8 mm pore size; BD Biosciences, San
Jose, CA, USA). For the migration assay, about 1105 osteosarcoma
cells were resuspended in 200 μl serum-free medium and placed
in the top chambers. DMEM (600 μl) containing 10% FBS was ﬁlled
into the bottom chambers. After 24 h of incubation at 37 °C, the
cells that did not migrate through the pores were removed by a
cotton swab, and cells on the lower surface of the membrane were
stained with crystal violet and counted. The invasion assay pro-
tocol was similar to that of the migration assay except that t the
cell culture insert surface was ﬁrst coated with Matrigel.
2.8. Statistics
All statistical analyses were performed using the SPSS 17.0
software package (SPSS, Chicago, IL, USA). The signiﬁcance of dif-
ferences between groups was estimated by Student's t-test and
Chi-square test. Survival curves were constructed with the Kaplan-
Meier method and compared by log-rank test. The signiﬁcance of
survival variables was evaluated using a multivariate Cox propor-
tional hazards regression analysis. Po0.05 was considered sta-
tistically signiﬁcant.Anatomic location 1.685 0.179 – –
Tumor grade 3.562 0.012 2.872 0.026
Tumor size 3.101 0.028 1.153 0.089
Clinical stage 5.969 o0.001 5.116 0.001
Distant metastasis 4.383 0.003 4.989 0.002
lncRNA-UCA1 level 5.746 o0.001 3.141 0.0153. Results
3.1. Increased UCA1 expression in osteosarcoma tissues and cell lines
UCA1 expression in osteosarcoma tissues and cell lines was
measured by qRT-PCR. We found that UCA1 expression in osteo-
sarcoma samples was signiﬁcantly higher than in adjacent non-
tumorous tissues (Fig. 1(A), Po0.001). In addition, UCA1 expres-
sion was signiﬁcantly increased in four osteosarcoma cell lines
compared to hFOB cells (Fig. 1(B), Po0.001). Since MG-63 cells
exhibited the highest UCA1 expression while HOS cells expressed
relatively low UCA1 levels among the four osteosarcoma cell lines,
these two cell lines were selected for the transfection of si-UCA1
or pcDNA-UCA1.Fig. 1. Expression of lncRNA-UCA1 in osteosarcoma tissues and cell lines. (A) UCA1 ex
tumorous tissues. (B) Increased UCA1 expression in four osteosarcoma cell lines compa3.2. Correlation between UCA1 expression and clinical features and
patient's prognosis
To assess the correlation of UCA1 expression with clin-
icopathologic characteristics, the osteosarcoma samples were
classiﬁed into high UCA1 expression group (n¼68) and low UCA1
expression group (n¼67) according to the median UCA1 expres-
sion level of all samples. Table 1 showed that high expression of
UCA1 was signiﬁcantly correlated with large tumor size (P
¼0.005), high tumor grade (P¼0.004), positive distant metastasispression was signiﬁcantly higher in osteosarcoma samples than in adjacent non-
red to normal osteoblast cells.
Fig. 3. Effects of lncRNA-UCA1 on the biological behaviors of osteosarcoma cells. (A) qRT-PCR analysis conﬁrmed increased UCA1 expression in HOS cells transfected with
pcDNA-UCA1, and decreased UCA1 expression in MG-63 cells transfected with si-UCA1. **Po0.01. (B) MTT assay showed that lncRNA-UCA1 promoted cell proliferation.
**Po0.01. (C) Flow cytometric analysis indicated that lncRNA-UCA1 reduced cell apoptosis. (D, E) Down-regulation of lncRNA-UCA1 impeded the invasion/migration of MG-
63 cells, while up-regulation of lncRNA-UCA1 promoted cell invasion/migration ability in HOS cells. **po0.01.
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Meier survival curves indicated that patients in low UCA1 ex-
pression group had better 5-year overall survival than those in
high UCA1 expression group (Po0.001, Fig. 2). Univariate Cox
proportional hazards analysis revealed that UCA1 expression, tu-
mor size, tumor grade, metastasis status, and clinical stage were
prognostic indicators (Table 2). Multivariate analysis conﬁrmed
UCA1 expression (P¼0.015) as an independent prognostic in-
dicator for overall survival of osteosarcoma patients in addition to
tumor grade (P¼0.026), tumor stage (P¼0.001), and distant me-
tastasis (P¼0.002; Table 2).
3.3. Effects of UCA1 on the biological behaviors of osteosarcoma cells
Fig. 3(A) conﬁrmed increased UCA1 expression in HOS cells after
pcDNA-UCA1 transfection, and decreased UCA1 expression in MG-
63 cells following si-UCA1 transfection. MTT assay showed that cell
proliferation was signiﬁcantly impaired in MG-63 cells transfected
with si-UCA1, while proliferation of HOS cells was increased after
pcDNA-UCA1 transfection (Fig. 3(B)). Flow cytometry demonstrated
promoted cell apoptosis after si-UCA1 transfection and reduced cell
apoptosis after pcDNA-UCA1 transfection (Fig. 3(C)). As shown in
Fig. 3(D) and (E), down-regulation of UCA1 impeded MG-63 cell
invasion and migration, while transfection of HOS cells with
pcDNA-UCA1 promoted cell invasion/migration ability.4. Discussion
It is urgent to develop novel targets for the diagnosis, treat-
ment, and prognosis of osteosarcoma. Increasing evidence has
demonstrated that lncRNAs play important roles in almost every
aspects of physiological and pathological processes in the human
body [6]. Changes of lncRNA expression are involved in cancer
formation and progression, which may provide a new but pro-
mising way to deal with cancer [26,27]. In the present study, we
observed high UCA1 expression in osteosarcoma tissues and cell
lines, providing the ﬁrst evidence that UCA1 upregulation was
closely associated with osteosarcoma initiation. Then we con-
ﬁrmed the correlation between increased UCA1 levels and ag-
gressive clinicopathological features of osteosarcoma samples.
UCA1 overexpression enhanced HOS cell proliferation, invasion
and migration, and inhibited cell apoptosis, whereas UCA1 silen-
cing in MG-63 cells showed opposite effects. These ﬁndings re-
vealed that UCA1 might contribute to osteosarcoma progression
and serve as a potential therapeutic target. Furthermore, osteo-
sarcoma patients with high UCA1 levels tended to have shorter
overall survival compared to patients with low UCA1 levels, and
multivariate Cox hazard regression analysis identiﬁed UCA1 ex-
pression as an independent prognostic indicator. To our knowl-
edge, this is the ﬁrst study to analyze the expression and clinical
signiﬁcance of UCA1 in osteosarcoma.
Our results are consistent with previous ﬁndings in other ma-
lignancies. Functional assays revealed that ectopic expression of
UCA1 promoted cell proliferation and/or reduced cell apoptosis in
non-small cell lung cancer [19], breast cancer [18], colorectal
cancer [28], and renal cell carcinoma [23]. Knockdown of UCA1
impaired cell invasion or migration ability in breast cancer [29],
esophageal squamous cell carcinoma [17], hepatocellular carcino-
ma[22], ovarian cancer [30], and melanoma [31]. UCA1 also de-
creased chemosensitivity in colorectal cancer[28], ovarian cancer
[24], and bladder cancer [32]. Clinical investigation demonstrated
that UCA1 overexpression was related to lymph node metastasis
and advanced FIGO stage in ovarian cancer [24]. Increased UCA1
expression correlated with worse differentiation, large tumor size,
deep local invasion, and advanced TNM stage in gastric cancer[33]. Further, high UCA1 expression was an unfavorable prognostic
factor for overall survival of patients with esophageal squamous
cell carcinoma [17], gastric cancer [33], colorectal cancer [21],
hepatocellular carcinoma [22], and epithelial ovarian cancer [34].
Taken together, these research indicated the oncogenic functions
of UCA1 in human cancers and suggested a potential application
for UCA1 in molecular targeted therapy.
We are aware of some limitations in our work. First, the clinical
part was a retrospective study, and the tumor sample size was
relatively small. Second, although we revealed the oncogene
function of UCA1 in osteosarcoma, its probable downstream
mediators are still unclear, and the underlying mechanisms by
which UCA1 promotes cancer development and progression re-
main to be thoroughly clariﬁed.
In summary, our study showed increased UCA1 expression in
osteosarcoma and its association with aggressive clin-
icopathological features and poor patient's prognosis. Regulation of
UCA1 expression inﬂuenced biological behaviors of osteosarcoma
cells. These ﬁndings indicate that UCA1 might be an important
molecular marker for prognostic evaluation of osteosarcoma and
serve as a potential therapeutic target for this disease.Conﬂicts of interest
The authors had no conﬂicts of interest to declare in relation to
this article.Acknowledgement
None.References
[1] D.S. Geller, R. Gorlick, Osteosarcoma: a review of diagnosis, management, and
treatment strategies, Clin. Adv. hematol. Oncol.: HO 8 (10) (2010) 705–718.
[2] S.S. Bielack, B. Kempf-Bielack, G. Delling, G.U. Exner, S. Flege, K. Helmke,
R. Kotz, M. Salzer-Kuntschik, M, Werner, W. Winkelmann, A. Zoubek,
H. Jurgens, K. Winkler, Prognostic factors in high-grade osteosarcoma of the
extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant
cooperative osteosarcoma study group protocols, J. Clin. Oncol.: Ofﬁcial J. Am.
Soc. Clin. Oncol. 20 (3) (2002) 776–790.
[3] K. Eppert, J.S. Wunder, V. Aneliunas, R. Kandel, I.L. Andrulis, von Willebrand
factor expression in osteosarcoma metastasis, Modern Pathol.: an Ofﬁcial J. U.
S. Can. Acad. Pathol. Inc 18 (3) (2005) 388–397.
[4] P.A. Meyers, Muramyl tripeptide (mifamurtide) for the treatment of osteo-
sarcoma, Expert Rev. anticancer Ther. 9 (8) (2009) 1035–1049.
[5] K.C. Wang, H.Y. Chang, Molecular mechanisms of long noncoding RNAs, Mol.
Cell 43 (6) (2011) 904–914.
[6] C. Ernst, C.C. Morton, Identiﬁcation and function of long non-coding, RNA,
Front. Cell. Neurosci. 7 (2013) 168.
[7] A. Fatica, I. Bozzoni, Long non-coding RNAs: new players in cell differentiation
and development, Nat. Rev. Genet. 15 (1) (2014) 7–21.
[8] T. Kunej, J. Obsteter, Z. Pogacar, S. Horvat, G.A. Calin, The decalog of long non-
coding RNA involvement in cancer diagnosis and monitoring, Crit. Rev. Clin.
Lab. Sci. 51 (6) (2014) 344–357.
[9] P.G. Maass, F.C. Luft, S. Bahring, Long non-coding RNA in health and disease, J.
Mol. Med. 92 (4) (2014) 337–346.
[10] A. Khandelwal, A. Bacolla, K.M. Vasquez, A. Jain, Long non-coding RNA: a new
paradigm for lung cancer, Mol. Carcinog. 54 (11) (2015) 1235–1251.
[11] M. Cui, L. You, X. Ren, W. Zhao, Q. Liao, Y. Zhao, Long non-coding RNA PVT1
and cancer, Biochem. Biophys. Res. Commun. 471 (1) (2016) 10–14.
[12] J. Sun, X. Wang, C. Fu, X. Wang, J. Zou, H. Hua, Z. Bi, Long noncoding RNA
FGFR3-AS1 promotes osteosarcoma growth through regulating its natural
antisense transcript FGFR3, Mol. Biol. Rep. (2016).
[13] B. Ma, M. Li, L. Zhang, M. Huang, J.B. Lei, G.H. Fu, C.X. Liu, Q.W. Lai, Q.Q. Chen, Y.
L. Wang, Upregulation of Long non-coding RNA TUG1 Correlates with poor
prognosis and Disease Status in Osteosarcoma, Tumour Biol.: J. Int. Soc. On-
codevelopmental Biol. Med. (2015).
[14] M. Cong, J. Li, R. Jing, Z. Li, Long non-coding RNA tumor suppressor Candidate
7 Functions as a tumor suppressor and Inhibits proliferation in Osteosarcoma,
Tumour Biol.: J. Int. Soc. Oncodevelopmental Biol. Med. (2016).
W. Li et al. / Journal of Bone Oncology 5 (2016) 80–85 85[15] C.L. Zhang, K.P. Zhu, G.Q. Shen, Z.S. Zhu, A Long non-coding RNA Contributes to
Doxorubicin Resistance of Osteosarcoma, Tumour Biol.: J. Int. Soc. Oncodeve-
lopmental Biol. Med. (2015).
[16] F. Wang, X. Li, X. Xie, L. Zhao, W. Chen, UCA1, a non-protein-coding RNA up-
regulated in bladder carcinoma and embryo, inﬂuencing cell growth and
promoting invasion, FEBS Lett. 582 (13) (2008) 1919–1927.
[17] J.Y. Li, X. Ma, C.B. Zhang, Overexpression of long non-coding RNA UCA1 pre-
dicts a poor prognosis in patients with esophageal squamous cell carcinoma,
Int. J. Clin. Exp. Pathol. 7 (11) (2014) 7938–7944.
[18] Y.L. Tuo, X.M. Li, J. Luo, Long noncoding RNA UCA1 modulates breast cancer
cell growth and apoptosis through decreasing tumor suppressive miR-143,
Eur. Rev. Med. Pharmacol. Sci. 19 (18) (2015) 3403–3411.
[19] W. Nie, H.J. Ge, X.Q. Yang, X. Sun, H. Huang, X. Tao, W.S. Chen, B. Li, LncRNA-
UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting
miR-193a-3p, Cancer Lett. 371 (1) (2016) 99–106.
[20] J. Gao, R. Cao, H. Mu, Long non-coding RNA UCA1 may be a novel diagnostic
and predictive biomarker in plasma for early gastric cancer, Int. J. Clin. Exp.
Pathol. 8 (10) (2015).
[21] Y. Han, Y.N. Yang, H.H. Yuan, T.T. Zhang, H. Sui, X.L. Wei, L. Liu, P. Huang, W.
J. Zhang, Y.X. Bai, UCA1, a long non-coding RNA up-regulated in colorectal
cancer inﬂuences cell proliferation, apoptosis and cell cycle distribution, Pa-
thology 46 (5) (2014) 396–401.
[22] F. Wang, H.Q. Ying, B.S. He, Y.Q. Pan, Q.W. Deng, H.L. Sun, J. Chen, X. Liu, S.
K. Wang, Upregulated lncRNA-UCA1 contributes to progression of hepatocel-
lular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK
signaling pathway, Oncotarget 6 (10) (2015) 7899–7917.
[23] Y. Li, T. Wang, Y. Li, D. Chen, Z. Yu, L. Jin, L. Ni, S. Yang, X. Mao, Y. Gui, Y. Lai,
Identiﬁcation of Long-non coding RNA UCA1 as an Oncogene in Renal Cell
Carcinoma, Mol. Med. Rep. (2016).
[24] L. Zhang, X. Cao, L. Zhang, X. Zhang, H. Sheng, K. Tao, UCA1 overexpression
predicts clinical outcome of patients with ovarian cancer receiving adjuvant
chemotherapy, Cancer Chemother. Pharmacol. 77 (3) (2016) 629–634.[25] X.Y. Na, Z.Y. Liu, P.P. Ren, R. Yu, X.S. Shang, Long non-coding RNA UCA1 con-
tributes to the progression of prostate cancer and regulates proliferation
through KLF4-KRT6/13 signaling pathway, Int. J. Clin. Exp. Med. 8 (8) (2015)
12609–12616.
[26] I. Dickson, Hepatocellular carcinoma: A role for lncRNA in liver cancer, Nat.
Rev. Gastroenterol. Hepatol. 13 (3) (2016) 122–123.
[27] M. Sun, F.Q. Nie, Z.X. Wang, W. De, Involvement of lncRNA dysregulation in
gastric cancer, Histol. Histopathol. 31 (1) (2016) 33–39.
[28] Z. Bian, L. Jin, J. Zhang, Y. Yin, C. Quan, Y. Hu, Y. Feng, H. Liu, B. Fei, Y. Mao,
L. Zhou, X. Qi, S. Huang, D. Hua, C. Xing, Z. Huang, LncRNA-UCA1 enhances cell
proliferation and 5-ﬂuorouracil resistance in colorectal cancer by inhibiting
miR-204–5p, Sci. Rep. 6 (2016) 23892.
[29] S. Chen, C. Shao, M. Xu, J. Ji, Y. Xie, Y. Lei, X. Wang, Macrophage inﬁltration
promotes invasiveness of breast cancer cells via activating long non-coding
RNA UCA1, Int. J. Clin. Exp. Pathol. 8 (8) (2015) 9052–9061.
[30] F. Wang, J. Zhou, X. Xie, J. Hu, L. Chen, Q. Hu, H. Guo, C. Yu, Involvement of
SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human
ovarian cancer cells, Neoplasma (2015).
[31] Y. Tian, X. Zhang, Y. Hao, Z. Fang, Y. He, Potential roles of abnormally expressed
long noncoding RNA UCA1 and Malat-1 in metastasis of melanoma, Melanoma
Res. 24 (4) (2014) 335–341.
[32] Y. Fan, B. Shen, M. Tan, X. Mu, Y. Qin, F. Zhang, Y. Liu, Long non-coding RNA
UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt
signaling, FEBS J. 281 (7) (2014) 1750–1758.
[33] Q. Zheng, F. Wu, W.Y. Dai, D.C. Zheng, C. Zheng, H. Ye, B. Zhou, J.J. Chen,
P. Chen, Aberrant expression of UCA1 in gastric cancer and its clinical sig-
niﬁcance, Clinical and translational oncology: ofﬁcial publication of the Fed-
eration of Spanish, Oncol. Soc. Natl. Cancer Inst. Mex. 17 (8) (2015) 640–646.
[34] Y. Yang, Y. Jiang, Y. Wan, L. Zhang, J. Qiu, S. Zhou, W. Cheng, UCA1 Functions as
a competing Endogenous RNA to Suppress epithelial Ovarian Cancer Metas-
tasis, Tumour Biol.: J. Int. Soc. Oncodev. Biol. Med. (2016).
